Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 study of ALN-TTRsc04 tin ATTR amyloidosis with cardiomyopathy

Next Previous
Trial Profile

A Phase 3 study of ALN-TTRsc04 tin ATTR amyloidosis with cardiomyopathy

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 26 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nucresiran (Primary)
  • Indications Cardiomyopathies; Transthyretin-related hereditary amyloidosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TRITON-CM
  • Sponsors Alnylam Pharmaceuticals

Most Recent Events

  • 17 May 2025 According to an Alnylam Pharmaceuticals media release, company will present the study design and rationale for TRITON-CM at the upcoming Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia.
  • 01 May 2025 According to an Alnylam Pharmaceuticals media release, Alnylam intends to initiate the TRITON-CM Phase 3 clinical trial of nucresiran in patients with ATTR-CM in the first half of 2025
  • 25 Feb 2025 According to an Alnylam Pharmaceuticals media release, if the trial is successful, is anticipated to lead to regulatory approval in approximately 2030.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top